J&J to buy Proteologix and its dual-targeting antibody drugs for $850M

cafead

Administrator
Staff member
  • cafead   May 16, 2024 at 12:22: PM
via Johnson & Johnson agreed to buy biotechnology startup Proteologix for $850 million in cash, gaining a portfolio of bispecific antibodies the privately held company has been developing for immune diseases.

article source